

Overview of a Conceptual Framework for Assessing the Hazards of Human Pharmaceuticals in the Environment*

Gerald Ankley (USA), Marsha Black (USA), Jeanne Garric (France), Thomas Hutchinson (UK), Taisen Iguchi (Japan)

*From a SETAC Pellston Workshop (July, 2003)

Historical ERAs for Human Active Pharmaceutical Ingredients (API)

 Prediction of potential environmental concentrations (PEC)

 Short-term lethality assays with algae, cladoceran and fish conducted if some threshold (e.g., 1 ppm) exceeded

 Little/no consideration of potential long-term toxicity, secondary impacts (e.g., via bioaccumulation), effects of metabolites, etc.

Little emphasis on possible ecological effects

Relevant Properties of APIs

- Present at low, often constant concentrations in water bodies
- Comprised of chemicals representative of relatively few MOA classes
- Usually designed not to be highly lethal
- Target specific biochemical pathways that can be highly conserved

Suggests potential for chronic (not acute) toxicity

Examples of Acute:Chronic Ratios (ACR) for APIs

Ethynylestradiol
 Copepod: 10.2 (Breitholz et al. 2001)
 Fish: 150,000 (Hutchinson et al. 2003)

Propranolol
 Amphipod: 59.6 (Huggett et al. 2002)
 Fish: >48,500 (Huggett et al. 2002)


The Challenge


Dealing with (potentially) 100s to1000s of chemicals, some that could have significant chronic toxicity

 Trying to protect all microbial, plant and animal species, with uncertainty about most sensitive phyla

The Proposed Solution

- Test a set of reference APIs with defined MOA
 Microbes, plants, and animals representative of phyla of concern
- Define logical suites of tests for untested APIs to estimate risk
- Conduct post hoc environmental monitoring to assess robustness of risk prediction





Test Design(s) and Endpoints

- Use existing methods with easily-tested species
- Conduct short-term and partial- or full-life cycle tests
- Focus on "traditional" whole-animal endpoints germane to risk assessments
- Supplement with diagnostic ("biomarker") endpoints that reflect MOA


Relevant Phyla for API Testing

Bacteria
Algae
Higher plants
Cnidarians
Molluscs
Annelids

Crustaceans
Insects
Echinoderms
Fish
Amphibians

Examples of Reference APIs

- Acetaminophen (analgesic)
- Diazepam (anti-epileptic)
- Ethynylestradiol (estrogen agonist)
- Fluoxetine (SSRI)
- Flutamide (androgen antagonist)
- Lovastatin (lipid metabolism)
- Mitomycin C (cytotoxin -- anti-cancer)
- Propranolol (beta (B2) blocker)
- Tetracycline (antibiotic)



Test Selection

Conduct "base test suite" to provide common baseline for APIs of potential ecological concern

Algal growth (72 h)
Cladoceran reproduction (7-21 d)
Fish partial-life cycle (7-10 d or 30-60 d)

Test Selection

Conduct "supplemental" tests selected based on chemical-specific considerations Sensitive species/endpoints identified in **MOA-based testing program** Unique physico-chemical characteristics Kow, photo-reactivity, etc. Assessment scenario


Test Selection

 Use data from drug registration process to help identify supplemental tests.

Examples of data collected include:
 Primary and secondary MOA
 Pharmacokinetics/dynamics
 Stability
 Biotic and abiotic metabolites

Examples of Supplemental Tests

- Fish reproduction for estrogen agonists
- Amphibian metamorphosis for thyroid-active APIs
- Blue-green algal tests for antibiotics
- Bioconcentration and/or sediment tests for chemicals with high Kow
- Assays with marine species for chemicals discharged into marine environments



Post Release Monitoring

 Ascertain that exposure predictions (PEC) are accurate

Document lack of (or degree of) impacts

May employ techniques/endpoints developed as part of original testing

Basic Field Monitoring Approaches

Target chemical monitoring

Parent and/or metabolites in water and/or biota

In situ biological monitoring
 Caged animals (fish, mollusks), with both apical and biomarker endpoints
 Ecological monitoring
 Evaluates condition potentially at cellular to the second secon

Evaluates condition potentially at cellular to community levels

Summary

- Focused, technically-rigorous approach emphasizes on testing based on MOA Identification of test "tool box" (species, endpoints) using model APIs/diverse phyla Selection of chemical-specific test suites based on physico-chemical properties and assessment scenario
 - Application of routine follow-up monitoring

Acknowledgements

 Society of Environmental Toxicology and Chemistry (SETAC), Organizer of Pellston Workshop

Workshop sponsors

40 workshop participants